Intercept Pharmaceuticals Form 4 / Mark Pruzanski ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pruzanski Mark

(Last)

(First)

(Middle)

C/O INTERCEPT PHARMACEUTICALS, INC.

305 MADISON AVENUE

(Street)

MORRISTOWN

07960

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
INTERCEPT PHARMACEUTICALS, INC. [ ICPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/08/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/08/2023		U		618,894	D	$19⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$266.01	11/08/2023		D			332	⁽²⁾	⁽²⁾	Common Stock	332	⁽²⁾	0	D
Option to Purchase Common Stock	$266.01	11/08/2023		D			5,401	⁽²⁾	⁽²⁾	Common Stock	5,401	⁽²⁾	0	D
Option to Purchase Common Stock	$161.16	11/08/2023		D			1,044	⁽²⁾	⁽²⁾	Common Stock	1,044	⁽²⁾	0	D
Option to Purchase Common Stock	$161.16	11/08/2023		D			31,506	⁽²⁾	⁽²⁾	Common Stock	31,506	⁽²⁾	0	D
Option to Purchase Common Stock	$94.29	11/08/2023		D			635	⁽²⁾	⁽²⁾	Common Stock	635	⁽²⁾	0	D
Option to Purchase Common Stock	$94.29	11/08/2023		D			29,865	⁽²⁾	⁽²⁾	Common Stock	29,865	⁽²⁾	0	D
Option to Purchase Common Stock	$107.18	11/08/2023		D			1,207	⁽²⁾	⁽²⁾	Common Stock	1,207	⁽²⁾	0	D
Option to Purchase Common Stock	$107.18	11/08/2023		D			38,793	⁽²⁾	⁽²⁾	Common Stock	38,793	⁽²⁾	0	D
Option to Purchase Common Stock	$58.74	11/08/2023		D			207	⁽²⁾	⁽²⁾	Common Stock	207	⁽²⁾	0	D
Option to Purchase Common Stock	$58.74	11/08/2023		D			45,293	⁽²⁾	⁽²⁾	Common Stock	45,293	⁽²⁾	0	D
Option to Purchase Common Stock	$110.8	11/08/2023		D			889	⁽²⁾	⁽²⁾	Common Stock	889	⁽²⁾	0	D
Option to Purchase Common Stock	$110.8	11/08/2023		D			12,811	⁽²⁾	⁽²⁾	Common Stock	12,811	⁽²⁾	0	D
Option to Purchase Common Stock	$99.66	11/08/2023		D			17,700	⁽²⁾	⁽²⁾	Common Stock	17,700	⁽²⁾	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

2. Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

	/s/ Rocco Venezia, as attorney-in-fact	11/13/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Intercept Pharmaceuticals (ICPT) Form 4INTERCEPT PHARMACEUTICALS / Mark Pruzanski ownership change